Find research datasets worth reusing

opencc-by-4.0May 2023View details →

How Safe and Technical Is Modified Dunn Osteotomy in the Management of Patients with SCFE: A Clinical Trial with Short Term Followup

This is the master datasheet used to support the findings of this study and Video 1 containing intraoperative scenes to show bleeding femoral head

opencc-by-4.0May 2023View details →

Analysis on CD8+/FOXP3+Ratio and Its Association with Primary Endocrine Therapy Resistance in Indonesian Luminal B Her-2 Negative BC Patients

Analysis on CD8+/FOXP3+Ratio and Its Association with Primary Endocrine Therapy Resistance in Indonesian Luminal B Her-2 Negative BC Patients

opencc-by-3.0-usApr 2023View details →

Rational Modification of Human Gut Microbial Metabolites by Dietary Resistant Starch in Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Feasibility Study

We conducted a prospective longitudinal feasibility study in patients undergoing allo-HCT for hematological malignancies to test the hypothesis that defined and consistent administration of resistant starch will rationally modify intestinal microbiota dependent metabolites, particularly the short chain fatty acids (SCFA), such as butyrate.  Ten adults undergoing human leukocyte antigen-matched, related-donor myeloablative allo-HCT were enrolled and received resistant potato starch (RPS) daily from day -7 to day 100 after allo-HCT.

dryad36/100

Industry funding of patient organisations in the United Kingdom: A retrospective study of commercial determinants, funding concentration and disease prevalence

Objectives – To assess the relationship between UK-based patient organisation funding and companies' commercial interests in rare and non-rare diseases in 2020. Design – Retrospective analysis of the value and volume of payments from pharmaceutical companies to patient organisations in the UK matched with data on the conditions supported by patient organisations and drugs in companies' approved portfolios and research and development pipelines. Setting – UK. Participants – 74 pharmaceutical companies making payments to 341 UK-based patient organisations. Main outcome measures – Alignment between the commercial interests of pharmaceutical companies and the disease area focus of patient organisations; difference in the volume and value of payments to patient organisations broken down by prevalence of conditions; industry funding concentration, measured as the number of companies funding each patient organisations, the share of overall industry funding coming from each contributing company and the share of industry funding of each organisation comprised by the single highest payments. Results – 1,422 payments were made by 74 companies to 341 patient organisations. Almost all funds (90%) from pharmaceutical companies were directed to patient organisations that are aligned with companies' approved drug portfolios and research and development pipelines. Despite rare diseases affecting less than 5% of the UK population, more than 20% of all payments were directed to patient organisations which target such conditions. Patient organisations focusing on rare diseases relied on payments from fewer companies (p-value = 0.0031) compared to organisations focusing on non-rare diseases. Conclusions – Companies predominantly funded patient organisations operating in therapeutic areas relevant to companies' portfolio or drug development pipeline. Patient organisations focusing on rare diseases received more funding relative to the number of patients affected by these conditions and relied more heavily on payments from fewer companies compared to organisations targeting non-rare diseases. Increased independence of patient organisations could help avoiding conflicts of interest.

opencc-zeroJun 2023View details →

Rhythm control and cardiovascular or cerebrovascular out-comes in patients with atrial fibrillation: A study of the CODE-AF registry

SUPPLEMENTARY MATERIAL   Rhythm control and cardiovascular or cerebrovascular outcomes in patients with atrial fibrillation: A study of the CODE-AF registry   Ho Gi Chung, MD; Junbeom Park; Jin-Kyu Park; Ki-Woon Kang; Jaemin Shim; Jin-Bae Kim; Jun Kim; Eue-Keun Choi; Hyung Wook Park; Young Soo Lee; Boyoung Joung <table> <tbody> <tr> <td> Supplementary Table 1. Subgroup analysis of primary outcome in rate- and rhythm-control group before overlap weighting. </td> </tr> </tbody> </table> <table> <tbody> <tr> <td> Supplementary Figure 1. Cumulative incidence of primary outcome in rhythm and rate control treatment groups before overlap weighting. </td> </tr> </tbody> </table> <table> <tbody> <tr> <td> Supplementary Figure 2. Cumulative incidence of secondary outcomes in rhythm and rate control treatment groups before overlap weighting. </td> </tr> </tbody> </table>

Validation of Polish-language questionnaires for assessing the quality of life of patients with Primary Ciliary Dyskinesia (PCD-QOL)

In recent years, questionnaires were published in English to assess the quality of life of patients with PCD for adults, adolescents aged 13-17, and children aged 6-12 and their caregivers. The aim of this study was to prepare a Polish version of the questionnaires and validate them in specific age groups with the participation of Polish patients with PCD.

PASS: A scoring system to evaluate persistent kidney injury in critically ill ICU adult patients

Acute Kidney Injury (AKI) and sepsis is highly prevalent in Intensive Care Units (ICU) and has direct effect on mortality and morbidity. We aimed to evaluate if course and recovery of  sepsis-AKI can be predicted using variables collected at the time of admission, and to develop a formula - Persistent AKI Scoring System (PASS) to predict recovery. 63 consecutive patients admitted for sepsis-AKI in our ICUs were evaluated over a period of 8 months. Baseline demographic and clinical/laboratory parameters ,including serum creatinine (SCr), Base Excess (BE), Plethysmographic Variability Index (PVI), Caval Index, R wave Variability (RVI), Mean Arterial Pressure (MAP) and Renal Resistivity Index (RI) using renal doppler and need for inotropes were assessed on admission. Patients were managed with standard protocols with fluid resuscitation and other specific therapy. After 6 of hours of fluid resuscitation, hemodynamic status and volume status of the patient was assessed. Patients were classified as Volume Responders or Non-responders depending on hemodynamic stabilization using parameters like MAP. Re- assessment of all the variables was done at 24 hours and 72 hours after admission. The primary outcome was persistent AKI after 72hrs. The secondary outcome was initiation of dialysis and death within 15 days of admission. 34 subjects recovered from AKI.  32 patients showed volume response with respect to hemodynamic parameters and 31 patients were non-responders. Response to fluid, MAP at admission, MAP after 6 hours, BE at admission, inotrope requirement, and PVI at admission did not correlate with recovery of AKI. RI, RVI and S Cr at admission significantly correlated with recovery from AKI These 3 parameters were evaluated further to develop the model for predicting recovery from AKI.• Score> 7.8 predicted recovery from AKI with sensitivity of 79.4%, specificity of 72.4%. PPV 81.8% and NPV 76.7%. PASS Score>7.8 had AUROC of 0.85. Multiple logistic regression showed that SCr< 2.36 mg%, RVI > 14.45 and RI < 0.8 on   admission correlated with recovery. PASS SCORE Formula was created using the same. CONCLUSION: PASS score can be a simple bed side method to reliably identify salvageable cases of sepsis-AKI, guiding fluid resuscitation and also aiding early referrals from rural to higher centers for better management.

Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients

Importance:  Obesity and metabolic disorders have been associated with an increased risk of cancer and with  poorer outcomes in many cohorts of breast cancer (BC) patients, with poor evidence from Mediterranean cohorts.  Objective: To investigate the prognostic potential of anthropometric variables, namely body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), as well as Metabolic Syndrome (MetS) and its components, in early BC patients living in a Southern Mediterranean region of Italy. Design: Prospective cohort study enrolling consecutive early BC patients who were treated between January 2009 and December 2013 in Southern Italy. Median follow-up was 11.8 years and ended on June 15th 2022. Physicians who measured the study variables were blinded to patient groupings. Setting: Multicenter study enrolling consecutive, early BC patients referred to specialized cancer centers. Participants: A total of 955 early BC patients consecutively treated at the Istituto Nazionale dei Tumori, “G. Pascale” and at the Policlinico University Hospital “Federico II”, Naples, Italy, were enrolled.  All study subjects provided written informed consent to participate.  Intervention(s) (for clinical trials) and exposure (for observational studies): Anthropometric measurements and indices (BMI, hip circumference and WC) were collected. MetS was defined according to NCEP-ATP III criteria. MetS components were categorized as 0, 1-2 or ≥3.  Main Outcomes  and Measures: Overall survival and BC-specific survival.  Results:  Mean age was 55.3 years (±12.5 years); 61% of patients were post-menopausal. At the end of follow-up, 208 (22%) patients had died, 131 (14%) of whom from BC. Obesity (BMI≥30 kg/m2) was found in 29% of enrolled patients (14% in pre- and 38% in post-menopause); 24% of patients met the criteria for a diagnosis of MetS (7% in pre- and 36% in post-menopause), whereas 1-2 MetS criteria were found in 53% of patients High WC or WHR were associated with a moderately increased risk of all-cause mortality (WC ≥ 88 cm, HR=1.39, 95%CI: 1.00-1.94; WHR > 0.85, HR=1.62, 95%CI: 1.12-2.37). Furthermore, an increased risk of all-cause mortality was observed with the presence of MetS (HR=1.61, 95%CI: 1.12-2.32). An increased BC-specific mortality risk was found in obese patients (BMI≥30 kg/m2, HR=1.72, 95%CI: 1.06-2.78) and in those with WC ≥88 (HR=1.71, 95%CI: 1.12-2.61). High WHR was also associated with increased risk of BC-specific mortality, both when evaluated as a categorical variable (WHR>0.85, HR=1.80, 95%CI: 1.13-2.86) and as a continuous variable (for each 0.1-U increase in WHR, HR=1.33, 95%CI: 1.08-1.63). The presence of MetS was associated with an 81% increased risk of BC-specific mortality (HR=1.81, 95%CI: 1.51-2.85).  These associations varied according to menopausal status. In particular, in pre-menopausal patients higher BMI was associated with an increased risk of both all-cause and BC-specific mortality (HR=1.43 and HR=1.58, respectively). In post-menopausal women an increased risk of all-cause mortality was found only in the presence of ≥3 MetS components (HR=2.77, 95%CI: 1.09-7.06). The associations among anthropometric variables and all-cause and BC-specific mortality also varied according to BC subtype. Triple negative BC was the only disease subtype that wasn’t independently associated with BMI, WC, WHR or MetS or all-cause and BC-specific mortality. Conclusions and Relevance: Central obesity and metabolic disorders result in a highly increased risk of BC death. The magnitude of this effect suggests that obesity may nullify the benefit of effective BC therapies. Active lifestyle interventions to maintain optimal body weight and to prevent MetS should be recommended for several expected beneficial effects, including a potential reduction in BC-specific mortality.

opencc-zeroJun 2023View details →

dryad36/100

Electrophysiological measurement results in patients with a missense variant in ACTG1

Introduction: This preliminary study identified a missense variant in ACTG1 (NM_001614.5) in a family with autosomal dominant non-syndromic hearing loss (ADNSHL). The responsiveness of the electrically stimulated cochlear nerve (CN) in two implanted participants with this missense change was also evaluated and reported. Methods: Genetic testing was done using a custom capture panel (MiamiOtoGenes) and whole exome sequencing. The responsiveness of the electrically-stimulated CN was evaluated in two members of this family (G1 and G4) using the electrically evoked compound action potential (eCAP). eCAP results from these two participants were compared with those measured three implanted patient populations: children with cochlear nerve deficiency, children with idiopathic hearing loss and normal-sized cochlear nerves, and postlingually deafened adults. Results: Sequencing of ACTG1 identified a missense c.737A>T (p. Gln246Leu) variant in ACTG1 (NM_001614.5) which is most likely the genetic cause of ADNSHL in this family. eCAP results measured in these two participants showed substantial variations. Discussion: The results indicated the missense c.737A>T (p. Gln246Leu) variant in ACTG1 (NM_001614.5) co-segregated with hearing loss in this family. The responsiveness of the electrically-stimulated CN can vary among patients with the same genetic variants, which suggests the importance of evaluating the functional status of the CN for individual CI patients.

opencc-by-4.0Dec 2022View details →

Data for "Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed"

This folder holds the data for the paper "Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed" (in submission) More information regarding this paper and the data is given in the GitHub repository (https://github.com/sgielis/WT1_TCR) The raw folder contains all MiXCR files for the two studied WT1 epitopes and two VZV epitopes. The VZV epitopes were not taken into account in this paper, but were used to build VZV-specific TCRex models for another paper [in submission]. Since all TCRs for the 4 epitopes were sequences together, this data was used for quality control purposes as explained in the paper. Following 4 folders are present: <ul> <li>run1: TCR data from the first run for WT1-126, WT1-37 and IE62</li> <li>run1_orf18: TCR data from the first run for ORF18</li> <li>run2: WT1-37 data filtered on high and low threshold gating.</li> <li>run 3: extra TCR data for WT1-126, WT1-37 aligned with MiXCR</li> </ul>

Pulse waveform and stroke volume/cardiac output measurements in healthy and hemodialysis patients

Pulse wave measurements made with the SphygmoCor device (SphygmoCor, AtCor Medical, Australia) and stroke volume measurements made with the PhysioFlow device. Measurements taken in healthy (18 observations) and hemodialysis patients (35 observations, measurements performed about 15 mins before the start, after the start, before the end and after the end of HD session).

Is Social Training Delivered with a Head-Mounted Display Suitable for Patients with Hereditary Ataxia?

This dataset  is related to 10 patients with different types of hereditary ataxia who performed a single VR-SPIRIT training session using the Oculus Quest, a Head Mounted Display. The VR- Social Prediction Improvement and Rehabilitation Intensive Training (VR-SPIRIT) is a rehabilitative intervention in virtual reality (VR) targeting social prediction to improve the use of contextual priors during prediction of others’ intentions in cerebellar patients. The aim here was to verify its usability and tolerability in patients with hereditary ataxia. To do this, after the session, patients answered a series of questionnaires to investigate the overall usability of the system and its potential effects in terms of cyber-sickness. The dataset includes a sheet related to demographic data, a sheet related to performance during the single session and one sheet for each questionnaire as follows: - System Usability Scale (SUS) - Suitability Evaluation Questionnaire (SEQ) - Simulator Sickness Questionnaire (SSQ) - Independent Television Commission-Sense of Presence Inventory (ITC-SOPI) - short-form of Positive Affect and Negative Affect Scales (PANAS). The details about data collection and all procedures are reported in the following manuscript, that we kindly ask you to cite if you use this dataset: Malerba, G.; Bellazzecca, S.; Urgesi, C.; Butti, N.; D’Angelo, M.G.; Diella, E.; Biffi, E. Is Social Training Delivered with a Head-Mounted Display Suitable for Patients with Hereditary Ataxia? Brain Sci. 2023, 13, 1017. https://doi.org/10.3390/ brainsci13071017

STROBE checklist_Study of compliance to treatment advised to patients attending medicine OPD in a tertiary care ruraral hospital

STROBE checklist of the study titled, "Study of compliance to treatment advised to patients attending medicine OPD in a tertiary care ruraral hospital."

Compliance worksheet_Study of compliance to treatment advised to patients attending medicine OPD in a tertiary care rural hospital

This is a worksheet of the data obtained from the questionnaires used for the study titled, "Study of compliance to treatment advised to patients attending  medicine OPD in a tertiary care rural hospital."

Assessment of the Quality of Life and Resilience in Ventilated Patients with COVID-19: Findings One year After Hospital Discharge

Assessment of the Quality of Life and Resilience in Ventilated Patients with COVID-19: Findings One year After Hospital Discharge This dataset was collected in a prospective cohort study to evaluate the quality of life and resilience of patients managed with invasive mechanical ventilation due to severe COVID-19, one year after hospital discharge. Methodology Design A prospective cohort study was conducted, and the present study received approval from the Ethics Committee of Universidad del Rosario (DVO005-1957- CV1534). Informed consent was obtained from each patient or their legal caregiver, which was given via telephone. Patients/Population Data were collected from patients who received MV support for respiratory failure secondary to critical illness due to COVID-19. The study included consecutively patients discharged alive from the Hospital Universitario Mayor Méderi located in the city of Bogota, Colombia from March 19, 2020, to April 30, 2021. Patients who passed away after discharge, those with whom telephone communication was not feasible, individuals with cognitive impairment preventing them from responding to the survey without obtaining information from a caregiver, and those who declined to participate in the study (as indicated by the patient and/or caregiver) were excluded from the final analysis. Intervention/Measurement Participants were administered a structured questionnaire that included three scales: PCFS (Post-COVID-19 functional Status Scale), EQ-5D-3L (EuroQol 5 dimensions 3 levels) (administered via telephone application), and CD-RISC (Connor-Davidson Resilience Scale). Permission for the non-commercial use of the EQ-5D-3L scale was obtained from the EuroQol Customer Portal (Registration No. 55265). Statistical Analysis The general characteristics of the population and the results of the PCFS, EQ-5D-3L, and CD-RISC were described. Continuous variables were presented as mean and standard deviation (SD) or median and interquartile range (IQR) depending on the data distribution. Categorical variables were described using absolute and relative frequencies. The PCFS was reported using a grading system ranging from Grade 0, indicating patients who were able to resume their daily activities without limitations, to Grade 4, representing severe functional limitations. The five dimensions of the EQ-5D-3L were considered as numerical variables and scored as follows: 1 for no alteration, 2 for moderate alteration, and 3 for severe alteration. The total score was computed by summing the scores from each dimension, ranging from 5 (indicating optimal quality of life) to 15 (indicating severely compromised quality of life). To assess the usefulness of the PCFS in measuring QoL, Pearson correlations were performed between the total score of the EQ-5D-3L and each individual dimension with the PCFS score. The CD-RISC and its 25 dimensions were evaluated as well. Each dimension was treated as a numerical variable and scored as follows: 0 for no alteration, 1 for mild alteration, 2 for moderate alteration, 3 for severe alteration, and 4 for critical alteration. The total CD-RISC score ranged from 0 (indicating no resilience) to 100 (indicating the best possible resilience). Furthermore, it was hypothesized that patients with higher resilience, as measured by the CD-RISC scale, would have better quality of life (QoL). Pearson correlations were examined between the PCFS score and the total CD-RISC score.

Trellis Single-Cell Screening Reveals Stromal Regulation of Patient-Derived Organoid Drug Responses

Patient-derived organoids (PDOs) can model personalized therapy responses, however current screening technologies cannot reveal drug response mechanisms or how tumor microenvironment cells alter therapeutic performance. To address this, we developed a highly-multiplexed mass cytometry platform to measure post translational modification (PTM) signaling, DNA-damage, cell-cycle activity, and apoptosis in >2,500 colorectal cancer (CRC) PDOs and cancer associated fibroblasts (CAFs) in response to clinical therapies at single-cell resolution. To compare patient- and microenvironment-specific drug responses in thousands of single-cell datasets, we developed Trellis — a highly-scalable, hierarchical tree-based treatment effect analysis method. Trellis single-cell screening revealed that on-target cell-cycle blockage and DNA-damage drug effects are common, even in chemorefractory PDOs. However, drug-induced apoptosis is rare, patient-specific, and aligns with cancer cell PTM signaling. We find that CAFs can regulate cancer cell plasticity — shifting proliferative stem cells to slow-cycling revival stem cells via YAP to protect cancer cells from chemotherapy.   This repo contains the processed scRNA-seq Scanpy AnnData objects generated from the study. More information describing the data can be found at: https://github.com/TAPE-Lab/Ramos-et-al-Trellis

An Assessment of Medication Errors among Pediatric Patients in Three Hospitals in Freetown Sierra Leone: Findings and Implications for a Low-Income Country

BackgroundPediatric patients are prone to medicine-related problems like medication errors (MEs), which can potentially cause harm. Yet, this has not been studied in this population in Sierra Leone. Therefore, this study investigated the prevalence and nature of MEs, including potential drug-drug interactions (pDDIs) in pediatric patients in three hospitals in Freetown, Sierra Leone.Methods: The study was conducted in three Hospitals among pediatric patients in Freetown and consisted of two phases. Phase one was a cross-sectional retrospective review of prescriptions for completeness and accuracy against standard prescription writing guidelines. Phase two was a point prevalence inpatient chart review of MEs that were categorized into prescription, administration, and dispensing errors and pDDIs. Data was analyzed using frequency, percentages, median, and interquartile range. Kruskal-Wallis H and Mann-Whitney U tests were used to compare the prescription accuracy between the hospitals, with p<0.05 considered statistically significant.Results: In phase one, while no prescription attained the global accuracy score (GAS) gold standard of 100%, 106 (29.0%) achieved the 80-100% mark. The patient 63 (17.2%), treatment 228 (62.3%), and prescriber 33 (9.0%) identifiers achieved an overall GAS range of 80-100%. Although the total GAS was not statistically significant (p=0.065), the date (p=0.041), patient (p=<0.001), treatment (p=0.022), and prescriber (p=<0.001) identifiers were statistically significant across the different hospitals. For phase two, the prevalence of MEs was 74 (56.1%), while that for pDDIs was 54 (40.9%). There was a statistically positive correlation between the occurrence of pDDI and the number of medicines prescribed (r=0.211, P=0.015).Conclusion: Low GAS depicts poor compliance with prescription writing guidelines and high prescribing errors. Medication errors were observed at each phase of the medication use cycle, while clinically significant pDDIs were also reported. Thus, there is a need for training on prescription writing guidelines and medication errors. Keywords:  Pediatrics, Prescription, Medication errors, Drug-drug interactions, Sierra Leone

opencc-by-4.0Aug 2023View details →

GERDAT021-Dataset for "Development and testing of the Outcome Prioritization Tool adjusted to older patients with cancer: A pilot study"

This dataset shows the data underlying the publication "Development and testing of the Outcome Prioritization Tool adjusted to older patients with cancer: A pilot study published in JGO on 21 July 2023, which can be found at <a href="https://doi.org/10.1016/j.jgo.2023.101590">10.1016/j.jgo.2023.101590</a>."